30 closest matches · ranked by relevance
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL · Leukemia Cutis · Recurrent Acute Myeloid Leukemia
Primary: Incidence of Dose-limiting Toxicities (DLTs) (Phase Ib)
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
AML
Primary: Complete Response Rate — 19 Participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Acute Myelogenous Leukemia
Primary: The Dose of Decitabine That Can be Safely Given With Vorinostat, Fludarabine, High Dose Cytarabine and G-CSF (FLAG) — 3; 20; 12; 0 Participants
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Complete Remission With or Without Incomplete Platelet Recovery — 1 Participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Acute Myelogenous Leukemia
Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants
Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia
Primary: Percentage of Patients we Are Able to Test and Initiate Treatment Within a 21 Day Period — 21 Participants
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Granulocytic Sarcoma · Recurrent Adult Acute Myeloid Leukemia
Primary: Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as…
Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Response Rate(CR/CRi) Rate — 6; 9 participants
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) — 400 mg/m^2
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Adult Acute Myeloid Leukemia in Remission · Recurrent Adult Acute Myeloid Leukemia
Primary: Relapse-free Survival in Days — 142 days
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Disease-free Survival — 8.87; 5.26 months — p=0.026